Unmet needs in bladder cancer in the immunotherapy era

Andrea Apolo

Despite there now being a variety of promising immunotherapies for bladder cancer, a large proportion of patients don’t respond to these. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, discusses this issue.

Share this video